These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 7742498)

  • 1. Pathology of the uterine body.
    Ferryman SR; Rollason TP
    Curr Opin Obstet Gynecol; 1994 Aug; 6(4):344-50. PubMed ID: 7742498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathology of the uterine body.
    Fox H
    Curr Opin Obstet Gynecol; 1991 Aug; 3(4):568-73. PubMed ID: 1652304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological findings and prognosis from uterine malignancy.
    Hernandez E
    Curr Opin Obstet Gynecol; 1993 Aug; 5(4):480-5. PubMed ID: 8400044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic aberrations in carcinomas of the uterine corpus.
    Micci F; Teixeira MR; Haugom L; Kristensen G; Abeler VM; Heim S
    Genes Chromosomes Cancer; 2004 Jul; 40(3):229-46. PubMed ID: 15139002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uterine sarcomas: a review.
    D'Angelo E; Prat J
    Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
    Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
    J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles.
    Ioffe YJ; Li AJ; Walsh CS; Karlan BY; Leuchter R; Forscher C; Cass I
    Gynecol Oncol; 2009 Dec; 115(3):466-71. PubMed ID: 19767065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of serous papillary uterine cancer.
    Schwartz PE
    Curr Opin Oncol; 2006 Sep; 18(5):494-9. PubMed ID: 16894299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
    Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
    Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas.
    Santin AD; Diamandis EP; Bellone S; Marizzoni M; Bandiera E; Palmieri M; Papasakelariou C; Katsaros D; Burnett A; Pecorelli S
    Am J Obstet Gynecol; 2006 May; 194(5):1296-302. PubMed ID: 16647913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
    Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
    Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
    Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
    Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.
    Abeler VM; Røyne O; Thoresen S; Danielsen HE; Nesland JM; Kristensen GB
    Histopathology; 2009 Feb; 54(3):355-64. PubMed ID: 19236512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas.
    Sherman ME; Sturgeon S; Brinton LA; Potischman N; Kurman RJ; Berman ML; Mortel R; Twiggs LB; Barrett RJ; Wilbanks GD
    Mod Pathol; 1997 Oct; 10(10):963-8. PubMed ID: 9346174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
    Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
    Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001.
    Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
    Gynecol Oncol; 2008 Oct; 111(1):74-81. PubMed ID: 18657852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects of uterine papillary serous carcinoma.
    Hamilton CA; Kapp DS; Chan JK
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):26-33. PubMed ID: 18197002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.